All In Biotech

Drug Trial Radar · NCT06916897

A Study to Evaluate Effect of Verapamil and Food of Sevasemten in Healthy Volunteers

A Phase 1, Open-Label Study to Evaluate the Effect of Verapamil and Food on the Pharmacokinetics of Sevasemten in Healthy Adult Subjects

Last checked: Nov 19, 2026Latest source record: Apr 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

42

Actual

Start

Jan 8, 2025

Primary completion

Feb 22, 2025

Study completion Feb 22, 2025

Sponsor

Lead sponsor
Edgewise Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Apr 8, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purposes of this Phase 1 study of sevasemten are to: 1. Evaluate the effect of multiple-dose administration of verapamil on the single-dose of sevasemten in healthy adults 2. Evaluate the safety and tolerability of a single dose of sevasemten administered with and without verapamil in healthy adult subjects. 3. Evaluate the safety and tolerability of a single dose of sevasemten administered with and without food in healthy adult subjects.

Conditions

  • Healthy Subjects

Interventions

  • sevasemtenDrug

    single dose 10mg sevasemten administered orally

  • VerapamilDrug

    multiple doses 240mg verapamil

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. PharmacokineticTime frame: Up to 46 days of monitoring
  2. PharmacokineticTime frame: Up to 46 days of monitoring
  3. PharmacokineticTime frame: up to 42 days of monitoring
  4. PharmacokineticTime frame: up to 42 days of monitoring
  5. PharmacokineticTime frame: up to 42 days of monitoring
  6. PharmacokineticTime frame: up to 42 days of monitoring

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Celerion

    Tempe, Arizona

  • Celerion

    Lincoln, Nebraska

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.